<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03598309</url>
  </required_header>
  <id_info>
    <org_study_id>MCC-19622</org_study_id>
    <secondary_id>8JK03</secondary_id>
    <nct_id>NCT03598309</nct_id>
  </id_info>
  <brief_title>Phase II Trial to Modulate Intermediate Endpoint Biomarkers in Former and Current Smokers</brief_title>
  <official_title>Phase II Trial of Investigational Agents to Modulate Intermediate Endpoint Biomarkers, Including Pulmonary Nodules, in Former and Current Smokers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>H. Lee Moffitt Cancer Center and Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>James and Esther King Biomedical Research Program</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>H. Lee Moffitt Cancer Center and Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to find out if an investigational combination drug called Lovaza&#xD;
      (made with fish oils)+Curcumin C3 Complex (made from a root called curcumin) can help reduce&#xD;
      the size of lung nodules. Researchers also want to find out if the combination of&#xD;
      Lovaza+Curcumin C3 Complex is safe and tolerable.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 5, 2019</start_date>
  <completion_date type="Anticipated">October 2023</completion_date>
  <primary_completion_date type="Anticipated">October 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Change in Bronchial Nodule Size</measure>
    <time_frame>6 months post treatment</time_frame>
    <description>Difference in the average change in bronchial nodule size from baseline to end of therapy at 6 months for each study arm. A lower size is taken to be the desired value for participants receiving study drug, assuming an increase in size for the placebo arm.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of Nodules ≥4 mm</measure>
    <time_frame>6 months post treatment</time_frame>
    <description>Number of nodules ≥4 mm per study arm, post treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of Adherence</measure>
    <time_frame>6 months post treatment</time_frame>
    <description>Rate of participant adherence per study arm. Proof of adherence based on study team pill counts, participant diet logs and pill logs at end of study, vs. data collected at midpoint.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Treatment Related Adverse Events (AEs)</measure>
    <time_frame>Up to 30 days post treatment, approximately 7 months</time_frame>
    <description>Safety of the combined agents (Curcumin C3 complex® + Lovaza®) at 2 dose arms vs. placebo as indicated by incidence of related adverse events and toxicities, monitored using Common Toxicity Criteria version 5.0.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Lung Diseases</condition>
  <condition>Lung Cancer, Protection Against</condition>
  <arm_group>
    <arm_group_label>Curcumin C3 complex® +Lovaza®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group A:&#xD;
4 grams Lovaza®, 2 grams twice a day (BID). 2 grams by mouth daily, AM and PM 8,000 mgs CUR Curcumin C3 complex® tablets, divided into 2 doses. 4 grams by mouth, twice a day, AM and PM.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Curcumin C3 complex® +Lovaza® +Placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group B:&#xD;
2 grams Lovaza®, 1 gram twice a day, AM and PM. 4,000 mgs CUR Curcumin C3 complex® tablets, 2,000 mgs twice a day, AM and PM.&#xD;
1 placebo capsule twice a day, AM and PM.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo only</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Placebo: Two matching placebo capsules twice a day (BID), taken by mouth, AM and PM</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Curcumin C3 complex®</intervention_name>
    <description>Groups A and B as outlined in study arm. Drug will be dispensed by investigational pharmacists and self-administered by the participants.</description>
    <arm_group_label>Curcumin C3 complex® +Lovaza®</arm_group_label>
    <arm_group_label>Curcumin C3 complex® +Lovaza® +Placebo</arm_group_label>
    <other_name>Curcuminoid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lovaza®</intervention_name>
    <description>Groups A and B as outlined in study arm. Drug will be dispensed by investigational pharmacists and self-administered by the participants.</description>
    <arm_group_label>Curcumin C3 complex® +Lovaza®</arm_group_label>
    <arm_group_label>Curcumin C3 complex® +Lovaza® +Placebo</arm_group_label>
    <other_name>Omega-3-Acid Ethyl Esters</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Groups B and Placebo as outlined in study arm. Drug will be dispensed by investigational pharmacists and self-administered by the participants.</description>
    <arm_group_label>Curcumin C3 complex® +Lovaza® +Placebo</arm_group_label>
    <arm_group_label>Placebo only</arm_group_label>
    <other_name>Pill with no drug or other active ingredients in it.</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female, 55 years of age or older&#xD;
&#xD;
          -  Former smokers and current enrolled in LDCT lung cancer screening or those who are&#xD;
             detected using a regular CT, and have Lung-RADS 3 category lesion(s), that would get a&#xD;
             6 month f/u LDCT or regular CT based on Lung-RADS recommendations or former and&#xD;
             current smokers enrolled in LDCT lung cancer screening, or regular CT and have&#xD;
             Lung-RADS 2 category lesions with persistent or slowly increasing part-solid or&#xD;
             non-solid lung nodule &gt;4mm mean diameter detected by two serial yearly screening low&#xD;
             dose CT or regular CT scans.&#xD;
&#xD;
          -  History of cigarette smoking with ≥ 20 pack years&#xD;
&#xD;
          -  All current smokers should accept to receive smoking cessation&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) Performance Status of less than or equal to&#xD;
             1&#xD;
&#xD;
          -  Able to swallow study pills&#xD;
&#xD;
          -  Able to undergo CT&#xD;
&#xD;
          -  Not allergic to components of study agents&#xD;
&#xD;
          -  Willing to discontinue current vitamin/mineral supplement use containing components of&#xD;
             study agents. A standard multivitamin supplement provided for the study&#xD;
&#xD;
          -  Willing to comply with proposed visit and treatment schedule&#xD;
&#xD;
          -  Able to understand and willing to sign a written informed consent document&#xD;
&#xD;
          -  Participants must have normal organ and marrow function&#xD;
&#xD;
          -  Willing to use contraception during the intervention period of 6 months (males and&#xD;
             females)&#xD;
&#xD;
          -  Not pregnant or lactating nor planning to become pregnant or lactate during the 6&#xD;
             month study intervention period..&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Invasive cancer diagnosis (excluding basal cell carcinoma or skin squamous cell&#xD;
             carcinoma) diagnosed within the last 2 years&#xD;
&#xD;
          -  Inability to undergo CT&#xD;
&#xD;
          -  Newly diagnosed nodule meeting Lung-RADS 4 criteria&#xD;
&#xD;
          -  Have taken doxycycline or tetracycline less than or equal to 2 weeks&#xD;
&#xD;
          -  Females- pregnant or lactating (throughout the duration of intervention of 6 months)&#xD;
&#xD;
          -  Unwilling to use effective form of birth control (Males and females) (throughout the&#xD;
             duration of intervention of 6 months).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nagi Kumar, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>H. Lee Moffitt Cancer Center and Research Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>H. Lee Moffitt Cancer Center and Research Institute</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kayoko Kennedy</last_name>
      <phone>813-745-1947</phone>
      <email>kayoko.kennedy@moffitt.org</email>
    </contact>
    <contact_backup>
      <last_name>Nagi Kumar, Ph.D.</last_name>
      <phone>813-745-6885</phone>
      <email>nagi.kumar@moffitt.org</email>
    </contact_backup>
    <investigator>
      <last_name>Nagi Kumar, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mark Alexandrow, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jhanelle Gray, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tawee Tanventyanon, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michael Alberts, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lary Robinson, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Farah Khalil, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Donald Klippenstein, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Matthew Schabath, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michael Schell, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.moffitt.org/research--clinical-trials/clinical-trials</url>
    <description>Moffitt Cancer Center Clinical Trials website</description>
  </link>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>July 13, 2018</study_first_submitted>
  <study_first_submitted_qc>July 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 26, 2018</study_first_posted>
  <last_update_submitted>June 10, 2021</last_update_submitted>
  <last_update_submitted_qc>June 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lung RADS 3</keyword>
  <keyword>Lung nodule</keyword>
  <keyword>Lung cancer risk</keyword>
  <keyword>Chemoprevention</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Curcumin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

